☆ 4.6 Review

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide

FRONTIERS IN NEUROLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Humoral- and T-Cell Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

Carla Tortorella et al.

Summary: This study evaluated the immune-specific response after full SARS-CoV-2 vaccination in patients with multiple sclerosis (MS) treated with different disease-modifying drugs. The results showed that mRNA vaccines induced both humoral and cell-mediated specific immune responses against viral spike proteins in the majority of patients with MS. These findings have important implications for promoting vaccination in all MS patients.

NEUROLOGY (2022)

添加到收藏夹

Review Clinical Neurology

COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments

Alice Laroni et al.

Summary: The COVID-19 pandemic poses a particular threat to those with chronic immune-mediated diseases, such as MS, who are often treated with immunomodulatory and immunosuppressive drugs. Careful management of immune-modulating treatment plans is necessary.

MULTIPLE SCLEROSIS JOURNAL (2021)

添加到收藏夹

Review Medicine, General & Internal

Diagnosis and Treatment of Multiple Sclerosis A Review

Marisa P. McGinley et al.

Summary: Multiple sclerosis is a neurodegenerative disease that affects the central nervous system, leading to physical disability, cognitive impairment and decreased quality of life. Current disease-modifying therapies can reduce relapse rates by 29% to 68% compared to placebo or active comparators.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu et al.

Summary: The study showed that CoronaVac vaccine is safe and well tolerated in older adults, and is able to induce neutralizing antibody levels. The highest dose of 3 μg of the vaccine can generate neutralizing antibody levels similar to the 6 μg dose, supporting the use of the 3 μg dose CoronaVac in phase 3 trials.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Clinical Neurology

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus

Diego Centonze et al.

Summary: COVID-19 emerged in Wuhan, China in December 2019 and quickly spread globally, with over 132 million cases and 2.8 million deaths recorded to date. A massive vaccination campaign has been initiated worldwide since the end of 2020, although there are concerns among neurologists about the safety and efficacy of vaccination in multiple sclerosis patients on immunomodulatory or immunosuppressive therapies.

JOURNAL OF NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021

Anat Achiron et al.

Summary: The study shows that the COVID-19 BNT162b2 vaccine is safe for patients with MS, with no increased risk of relapse activity observed after vaccination.

MULTIPLE SCLEROSIS JOURNAL (2021)

添加到收藏夹

Review Clinical Neurology

COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review

Maryam Sharifian-Dorche et al.

Summary: This study reviews the impact of COVID-19 on patients with demyelinating diseases of the central nervous system like Multiple Sclerosis (MS) or Neuromyelitis Optica Spectrum Disorder (NMOSD), finding no clear relationship between disease-modifying therapies (DMT) use and the course of COVID-19. Risk factors for severe COVID-19 included age, higher EDSS scores, cardiac comorbidities, and obesity. Despite infection risks, most patients chose to continue DMT due to concerns about relapse or worsened MS symptoms, with some immune response attenuation seen in patients on specific medications post-infection.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

添加到收藏夹

Letter Clinical Neurology

Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis

Giulio Disanto et al.

JAMA NEUROLOGY (2021)

添加到收藏夹

Letter Clinical Neurology

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab

Fabio Buttari et al.

Summary: For MS patients treated with immunosuppressive drugs, the timing of vaccination may be more crucial than lymphocyte count in determining the response to the vaccine.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study

William L. Conte

Summary: This study suggests that MS patients treated with OCR within 6 months of a COVID-19 infection have decreased odds of developing antibodies to SARS-CoV-2 compared to other disease modifying therapies. Further research is needed to analyze spike protein antibody formation in response to SARS-CoV-2 vaccines for patients on OCR.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

添加到收藏夹

Review Immunology

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

Samir Andrade Mendonca et al.

Summary: Adenoviral vector vaccines have been extensively studied as candidates for COVID-19, showing potential to induce potent and balanced immune responses. Several of these vaccines are currently in human clinical trials, supported by government agencies for rapid translational development.

NPJ VACCINES (2021)

添加到收藏夹

Meeting Abstract Clinical Neurology

Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab

Antonio Gallo et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

添加到收藏夹

Article Clinical Neurology

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Anat Achiron et al.

Summary: The study found that after receiving the COVID-19 vaccine, MS patients who were either untreated or treated with cladribine showed a high level of protective humoral immunity, similar to healthy subjects. However, only a small percentage of MS patients treated with ocrelizumab and fingolimod developed a humoral immune response.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

添加到收藏夹

Review Immunology

Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective

Dejan Jakimovski et al.

VACCINES (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Jun Lan et al.

NATURE (2020)

添加到收藏夹

Article Clinical Neurology

COVID-19 and MS disease-modifying therapies

Joseph R. Berger et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

添加到收藏夹

Article Clinical Neurology

Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination

Crystal Zheng et al.

CNS DRUGS (2020)

添加到收藏夹

Editorial Material Biochemistry & Molecular Biology

Why and How Vaccines Work

Akiko Iwasaki et al.

CELL (2020)

添加到收藏夹

Article Clinical Neurology

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis The VELOCE study

Amit Bar-Or et al.

NEUROLOGY (2020)

添加到收藏夹

Article Immunology

The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia

Maria Rosa Ciardi et al.

JOURNAL OF NEUROIMMUNOLOGY (2020)

添加到收藏夹

Letter Clinical Neurology

Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide

Luca Bollo et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)

添加到收藏夹

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Clinical Neurology

Effects of MS disease-modifying therapies on responses to vaccinations: A review

John Robert Ciotti et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

添加到收藏夹

Article Immunology

Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection

Michael W. Russell et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Review Medicine, General & Internal

Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases

Nora Moehn et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Article Neurosciences

Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies

Christoph Metze et al.

CNS NEUROSCIENCE & THERAPEUTICS (2019)

添加到收藏夹

Article Clinical Neurology

Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Mauricio F. Farez et al.

NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy

H. K. Olberg et al.

EUROPEAN JOURNAL OF NEUROLOGY (2018)

添加到收藏夹

Review Medicine, General & Internal

Understanding modern-day vaccines: what you need to know

Volker Vetter et al.

ANNALS OF MEDICINE (2018)

添加到收藏夹

Article Clinical Neurology

Immune response to vaccines is maintained in patients treated with dimethyl fumarate

Christian von Hehn et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)

添加到收藏夹

Review Clinical Neurology

Vaccines in Multiple Sclerosis

Eric M. L. Williamson et al.

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2016)

添加到收藏夹

Article Clinical Neurology

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

Ludwig Kappos et al.

NEUROLOGY (2015)

添加到收藏夹

Article Clinical Neurology

Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens

Amit Bar-Or et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)

添加到收藏夹

Review Pharmacology & Pharmacy

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis

Amit Bar-Or et al.

DRUGS (2014)

添加到收藏夹

Article Clinical Neurology

Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis

Michael Kaufman et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)

添加到收藏夹

Article Clinical Neurology

Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study

Henning K. Olberg et al.

MULTIPLE SCLEROSIS JOURNAL (2014)

添加到收藏夹

Article Clinical Neurology

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

Amit Bar-Or et al.

NEUROLOGY (2013)

添加到收藏夹

Article Clinical Neurology

Immune competence after alemtuzumab treatment of multiple sclerosis

Claire L. McCarthy et al.

NEUROLOGY (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Preserved Antigen-Specific Immune Response in Patients with Multiple Sclerosis Responding to IFNβ-Therapy

Matthias Mehling et al.

PLOS ONE (2013)

添加到收藏夹

Article Clinical Neurology

Antigen-Specific Adaptive Immune Responses in Fingolimod-Treated Multiple Sclerosis Patients

Matthias Mehling et al.

ANNALS OF NEUROLOGY (2011)

添加到收藏夹

Article Clinical Neurology

Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a

SR Schwid et al.

NEUROLOGY (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.